ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors
Glucocorticoid receptor (GR) upregulation is a mechanism of resistance to taxane chemotherapy in preclinical cancer models. ORIC-101 is a small molecule GR inhibitor. In this phase 1 study, ORIC-101 plus nab-paclitaxel did not show meaningful clinical benefit in patients who previously progressed on taxanes despite successful GR pathway downregulation.
Authors
- Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
- Shivaani Kummar (ORCID: https://orcid.org/0000-0001-6906-1627)
- Manish R. Patel (ORCID: https://orcid.org/0000-0001-6836-2364)
- Christopher T. Chen (ORCID: https://orcid.org/0000-0001-8962-3527)
- S. Lindsey Davis (ORCID: https://orcid.org/0000-0003-3899-9481)
- Edna Chow Maneval (ORCID: https://orcid.org/0000-0001-8131-755X)
- Haiying Zhou (ORCID: https://orcid.org/0000-0002-0440-9204)
- Maureen Duff
- Vishesh Khanna (ORCID: https://orcid.org/0000-0001-8930-7401)
- Anneleen Daemen (ORCID: https://orcid.org/0000-0001-6287-7105)
- Nadine S. Jahchan (ORCID: https://orcid.org/0000-0002-0610-5001)
- Melissa R. Junttila (ORCID: https://orcid.org/0000-0003-3538-1192)
- Raghad M. Abdul-Karim
- Pratik S. Multani (ORCID: https://orcid.org/0000-0001-8358-3560)
- Vaia Florou (ORCID: https://orcid.org/0000-0001-5558-753X)
- Alexander I. Spira (ORCID: https://orcid.org/0000-0003-1303-0447)
- Aleksandr Pankov
- Anthony W. Tolcher (ORCID: https://orcid.org/0000-0002-6322-9721)
- David Sommerhalder (ORCID: https://orcid.org/0000-0002-7033-9064)
- Wayne Kong
- Shravani Barkund (ORCID: https://orcid.org/0009-0001-1620-0942)
- Rongda Xu (ORCID: https://orcid.org/0000-0003-0719-7005)
- Pamela N. Münster (ORCID: https://orcid.org/0000-0002-2074-0984)
- Shekeab Jauhari (ORCID: https://orcid.org/0000-0001-7484-1214)
- Naoto Tada Ueno (ORCID: https://orcid.org/0000-0002-0166-7275)
- Jian Wang (ORCID: https://orcid.org/0009-0004-9735-2578)
- Erica L. Jackson (ORCID: https://orcid.org/0000-0002-7100-8021)
- Douglas W. Orr (ORCID: https://orcid.org/0009-0003-0262-970X)
- Jessica D. Sun (ORCID: https://orcid.org/0000-0002-9844-9767)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Oregon Health & Science University (US)
- University of California, San Francisco (US)
- University of Utah (US)
- Texas Oncology (US)
- Huntsman Cancer Institute (US)
- Mary Crowley Cancer Research Center (US)
- Sarah Cannon (US)
- Threshold Pharmaceuticals (United States) (US)
- Florida Cancer Specialists & Research Institute (US)
- Virginia Cancer Specialists (US)
- University of Colorado Cancer Center (US)
- Tennessee Oncology (US)
- Scorpion Therapeutics (United States) (US)
- The US Oncology Network (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- University of Colorado Anschutz Medical Campus (US)
- Sunesis (United States) (US)
- University of Colorado Denver (US)
- Stanford University (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0115
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00